Table 3.
Univariate and multivariate Cox regression analysis on OS, PFS and IHPFS in the whole cohort
| Variable | OS (N = 114, events = 91) | PFS (N = 114, events = 110) | IHPFS (N = 114, events = 110) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Univariable model | Multivariable model | Univariable model | Multivariable model | Univariable model | Multivariable model | |||||||
| HR (95% CI) | Pa | HR (95% CI) | pa | HR (95% CI) | pa | HR (95% CI) | pa | HR (95% CI) | pa | HR (95% CI) | pa | |
| Group (refer to LEN) | 0.43 (0.27–0.70) | 0.001 | 0.37 (0.23–0.60) | 0.000 | 0.41 (0.27–0.63) | 0.000 | 0.33 (0.21–0.51) | 0.000 | 0.38 (0.25–0.59) | 0.000 | 0.29 (0.18–0.45) | 0.000 |
| Gender (refer to Male) | 1.21 (0.65–2.28) | 0.548 | 1.53 (0.87–2.70) | 0.145 | 1.28 (0.73–2.25) | 0.390 | ||||||
| Age (refer to < 55 years) | 1.01 (0.67–1.52) | 0.960 | 1.11 (0.76–1.62) | 0.605 | 1.10 (0.74–1.60) | 0.668 | ||||||
| Etiology (refer to HBV) | 1.49 (0.64–3.45) | 0.356 | 0.93 (0.41–2.12) | 0.864 | 0.96 (0.42–2.20) | 0.924 | ||||||
| Child–Pugh classification (refer to A) | 1.87 (1.09–3.23) | 0.024 | 1.15 (0.63–2.11) | 0.655 | 1.57 (0.93–2.65) | 0.089 | 1.28 (0.74–2.20) | 0.382 | 1.68 (1.00–2.84) | 0.052 | 1.38 (0.80–2.38) | 0.248 |
| ECOG PS (refer to 0) | 1.71 (1.12–2.62) | 0.013 | 1.37 (0.85–2.20) | 0.199 | 1.35 (0.92–1.98) | 0.127 | 1.34 (0.91–1.97) | 0.135 | ||||
| Number of tumors (refer to ≤ 3) | 1.79 (1.18–2.71) | 0.006 | 1.73 (1.11–2.72) | 0.017 | 1.83 (1.25–2.68) | 0.002 | 2.05 (1.36–3.09) | 0.001 | 1.77 (1.21–2.59) | 0.004 | 2.05 (1.35–3.12) | 0.001 |
| Tumor size (refer to < 5 cm) | 1.21 (0.92–1.61) | 0.180 | 1.11 (0.86–1.44) | 0.429 | 1.10 (0.84–1.42) | 0.491 | ||||||
| PVTT (refer to Vp1) | 2.16 (1.56–2.99) | 0.000 | 1.95 (1.37–2.77) | 0.000 | 1.50 (1.14–1.97) | 0.004 | 1.52 (1.13–2.04) | 0.005 | 1.46 (1.11–1.92) | 0.008 | 1.45 (1.08–1.95) | 0.014 |
| ALBI grade (refer to 1) | 1.40 (0.88–2.23) | 0.155 | 1.10 (0.73–1.67) | 0.641 | 1.07 (0.71–1.62) | 0.742 | ||||||
| AFP (refer t ≤ 200 ng/mL) | 1.54 (1.02–2.32) | 0.039 | 1.24 (0.81–1.89) | 0.317 | 1.57 (1.07–2.31) | 0.021 | 1.39 (0.94–2.05) | 0.097 | 1.51 (1.03–2.21) | 0.036 | 1.37 (0.92–2.02) | 0.119 |
| PLT (refer to < 100 × 109/L) | 0.81 (0.51–1.31) | 0.396 | 0.91 (0.59–1.42) | 0.684 | 0.93 (0.59–1.44) | 0.732 | ||||||
| WBC (refer to < 4 × 109/L) | 0.84 (0.54–1.30) | 0.429 | 0.69 (0.46–1.04) | 0.078 | 0.67 (0.43–1.02) | 0.063 | 0.68 (0.45–1.03) | 0.072 | 0.66 (0.43–1.02) | 0.063 | ||
| Previous local treatment (refer to Absence) | 0.77 (0.39–1.53) | 0.454 | 0.95 (0.52–1.74) | 0.870 | 0.86 (0.47–1.57) | 0.623 | ||||||
HBV hepatitis b virus, ECOG Eastern Cooperative Oncology Group, PS performance status, MVI macrovascular invasion, ALBI grade albumin-bilirubin grade, AFP alpha-fetoprotein, PLT platelet, WBC white blood cell, LEN lenvatinib, TAE transcatheter arterial embolization, SBRT stereotactic body radiotherapy, LEN lenvatinib, PFS progression-free survival, OS overall survival, IHPFS intrahepatic progression-free survival
aBold values indicate statistical significance